440 reports of this reaction
3.9% of all BRIMONIDINE reports
#3 most reported adverse reaction
HYPERSENSITIVITY is the #3 most commonly reported adverse reaction for BRIMONIDINE, manufactured by Padagis Israel Pharmaceuticals Ltd. There are 440 FDA adverse event reports linking BRIMONIDINE to HYPERSENSITIVITY. This represents approximately 3.9% of all 11,162 adverse event reports for this drug.
Patients taking BRIMONIDINE who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is moderately reported among BRIMONIDINE users, representing a notable but not dominant share of adverse events.
In addition to hypersensitivity, the following adverse reactions have been reported for BRIMONIDINE:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 440 FDA reports for BRIMONIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 3.9% of all adverse event reports for BRIMONIDINE, making it one of the most commonly reported side effect.
If you experience hypersensitivity while taking BRIMONIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.